Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
A phase II trial evaluating the safety and effectiveness of the AastromReplicell system for augmentation of low-dose blood stem cell transplantation
Autore:
Pecora, AL; Stiff, P; LeMaistre, CF; Bayer, R; Bachier, C; Goldberg, SL; Parthasarathy, M; Jennis, AA; Smith, AK; Douville, J; Chen, B; Armstrong, RD; Mandalam, RK; Preti, R;
Indirizzi:
Hackensack Univ, Med Ctr, Dept Med, Hackensack, NJ USA Hackensack Univ Hackensack NJ USA Med Ctr, Dept Med, Hackensack, NJ USA Loyola Univ, Sch Med, Dept Med, Maywood, IL 60153 USA Loyola Univ MaywoodIL USA 60153 Sch Med, Dept Med, Maywood, IL 60153 USA SW Texas Canc Inst, San Antonio, TX USA SW Texas Canc Inst San Antonio TXUSA xas Canc Inst, San Antonio, TX USA Aastrom Biosci, Ann Arbor, MI USA Aastrom Biosci Ann Arbor MI USAAastrom Biosci, Ann Arbor, MI USA Progenitor Cell Therapy, Hackensack, NJ USA Progenitor Cell Therapy Hackensack NJ USA ll Therapy, Hackensack, NJ USA
Titolo Testata:
BONE MARROW TRANSPLANTATION
fascicolo: 3, volume: 28, anno: 2001,
pagine: 295 - 303
SICI:
0268-3369(200108)28:3<295:APITET>2.0.ZU;2-Q
Fonte:
ISI
Lingua:
ENG
Soggetto:
BREAST-CANCER PATIENTS; BONE-MARROW TRANSPLANTATION; COLONY-STIMULATING FACTOR; PROGENITOR CELLS; G-CSF; MALIGNANT-LYMPHOMA; PLATELET RECOVERY; STROMAL CELLS; CHEMOTHERAPY; MOBILIZATION;
Keywords:
ex vivo expansion; low-dose blood stem cells;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
39
Recensione:
Indirizzi per estratti:
Indirizzo: Pecora, AL 20 Prospect St,Suite 400, Hackensack, NJ 07601 USA 20 ProspectSt,Suite 400 Hackensack NJ USA 07601 NJ 07601 USA
Citazione:
A.L. Pecora et al., "A phase II trial evaluating the safety and effectiveness of the AastromReplicell system for augmentation of low-dose blood stem cell transplantation", BONE MAR TR, 28(3), 2001, pp. 295-303

Abstract

To reduce the number of apheresis procedures and maintain the usual rate of hematopoietic recovery in patients treated with high-dose chemotherapy, we studied the effect of adding a small volume of ex vivo expanded bone marrow to low doses of CD34(+) blood stem cells. Thirty-four patients with breast cancer received G-CSF (10 mug/kg/day) priming followed by a limited volume (50-100 ml) bone marrow aspiration and standard 10-liter aphereses. Marrow was expanded ex vivo using the AastromReplicell system and infused alongwith low doses of blood-derived CD34(+) cells, collected in one apheresis. Thirty-one evaluable patients received a median CD34(+) blood stem cell dose of 0.7 x 10(6)/kg (range, 0.2-2.5) and 4.7 x 10(7) nucleated cells/kg (range, 1.98-8.7) of ex vivo expanded marrow. All patients recovered with normal blood counts and engrafted 500 neutrophils/mul and 20 000 platelets/mulin a median of 10 and 13 days, respectively. Multivariate analysis revealed that, in addition to CD34(+) lineage negative cell quantity, the quantityof stromal progenitors contained in the ex vivo expanded product correlated with engraftment outcome (r = 0.551, P = 0.004). Our results indicate that ex vivo expanded bone marrow is capable of facilitating engraftment when combined with low doses of mobilized blood derived CD34(+) cells.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 27/09/20 alle ore 07:15:21